Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Sung, MM; Byrne, NJ; Kim, TT; Levasseur, J; Masson, G; Boisvenue, JJ; Febbraio, M; Dyck, JR.
Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure.
Am J Physiol Heart Circ Physiol. 2017; 312(3): H552-H560.
Doi: 10.1152/ajpheart.00626.2016
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Byrne Nikole
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Previous studies have shown that loss of CD36 protects the heart from dysfunction induced by pressure overload in the presence of diet-induced insulin resistance and/or obesity. The beneficial effects of CD36 ablation in this context are mediated by preventing excessive cardiac fatty acid (FA) entry and reducing lipotoxic injury. However, whether or not the loss of CD36 can prevent pressure overload-induced cardiac dysfunction in the absence of chronic exposure to high circulating FAs is presently unknown. To address this, we utilized a tamoxifen-inducible cardiomyocyte-specific CD36 knockout (icCD36KO) mouse and genetically deleted CD36 in adulthood. Control mice (CD36 floxed/floxed mice) and icCD36KO mice were treated with tamoxifen and subsequently subjected to transverse aortic constriction (TAC) surgery to generate pressure overload-induced cardiac hypertrophy. Consistent with CD36 mediating a significant proportion of FA entry into the cardiomyocyte and subsequent FA utilization for ATP production, hearts from icCD36KO mice were metabolically inefficient and displayed signs of energetic stress, including activation of the energetic stress kinase, AMPK. In addition, impaired energetics in icCD36KO mice contributed to a rapid progression from compensated hypertrophy to heart failure. However, icCD36KO mice fed a medium-chain FA diet, whereby medium-chain FAs can enter into the cardiomyocyte independent from CD36, were protected from TAC-induced heart failure. Together these data suggest that limiting FA uptake and partial inhibition of FA oxidation in the heart via CD36 ablation may be detrimental for the compensated hypertrophic heart in the absence of sufficiently elevated circulating FAs to provide an adequate energy source.NEW & NOTEWORTHY Limiting CD36-mediated fatty acid uptake in the setting of obesity and/or insulin resistance protects the heart from cardiac hypertrophy and dysfunction. However, cardiomyocyte-specific CD36 ablation in the absence of elevated circulating fatty acid levels accelerates the progression of pressure overload-induced cardiac hypertrophy to systolic heart failure.
- Find related publications in this database (using NLM MeSH Indexing)
- AMP-Activated Protein Kinases - metabolism
- Adenosine Triphosphate - biosynthesis
- Animals - administration & dosage
- CD36 Antigens - genetics
- Cardiomegaly - chemically induced, genetics, pathology
- Disease Progression - administration & dosage
- Energy Metabolism - genetics
- Estrogen Antagonists - administration & dosage
- Heart Failure - genetics, pathology
- Male - administration & dosage
- Mice - administration & dosage
- Mice, Inbred C57BL - administration & dosage
- Mice, Knockout - administration & dosage
- Myocardium - pathology
- Myocytes, Cardiac - pathology
- Tamoxifen - administration & dosage
- Triglycerides - blood
- Find related publications in this database (Keywords)
- CD36
- hypertrophy
- fatty-pacid metabolism
- pressure overload